Cargando…

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine Tumor Society estimates that the United States has more than 150,000 gastroenteropancreatic NET patients. About 10% of metastatic NETs can be unknown primary, and due to their rar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauhan, Aman, Farooqui, Zainab, Murray, Le Aundra, Weiss, Heidi L., War Myint, Zin, Raajasekar, Arun Kumar A., Evers, B. Mark, Arnold, Susanne, Anthony, Lowell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964580/ https://www.ncbi.nlm.nih.gov/pubmed/29853889 http://dx.doi.org/10.1155/2018/3519247

Ejemplares similares

Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2019)

Global burden of neuroendocrine tumors and changing incidence in Kentucky
por: Chauhan, Aman, et al.
Publicado: (2018)

Neuroendocrine Tumors in Pediatrics
por: Farooqui, Zainab Azam, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)
por: Noorali, Sima, et al.
Publicado: (2021)

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors
por: Al-Toubah, Taymeyah, et al.
Publicado: (2022)

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
por: Chauhan, Aman, et al.
Publicado: (2018)

Management of Large Cell Neuroendocrine Carcinoma
por: Corbett, Virginia, et al.
Publicado: (2021)

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
por: Kotteas, Elias A, et al.
Publicado: (2016)

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature
por: Chauhan, Aman, et al.
Publicado: (2017)

Gynecologic large cell neuroendocrine carcinoma: A review
por: Burkeen, Grant, et al.
Publicado: (2020)

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
por: Ünal, Çağlar, et al.
Publicado: (2023)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
por: Chauhan, Aman, et al.
Publicado: (2022)

Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis
por: Lu, Yaoheng, et al.
Publicado: (2018)

Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience
por: Douangprachanh, Sathathone, et al.
Publicado: (2022)

Biliary tract large cell neuroendocrine carcinoma: current evidence
por: Raiker, Riva, et al.
Publicado: (2019)

Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients
por: Chauhan, Aman, et al.
Publicado: (2020)

PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors
por: Chow, Zeta, et al.
Publicado: (2021)

Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review
por: Zhang, Bin, et al.
Publicado: (2019)

Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary
por: Hendifar, Andrew E., et al.
Publicado: (2019)

Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response
por: Owen, Dwight H., et al.
Publicado: (2017)

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
por: Jeong, H., et al.
Publicado: (2021)

MON-406 Two Cases of Aggressive Corticotroph Pituitary Tumors Treated with Capecitabine and Temozolomide
por: Tateno, Tae, et al.
Publicado: (2019)

Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review
por: Ishida, Atsushi, et al.
Publicado: (2022)

A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report
por: Özdirik, Burcin, et al.
Publicado: (2021)

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
por: Couronne, Thomas, et al.
Publicado: (2020)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
por: Ferrarotto, Renata, et al.
Publicado: (2013)

Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen
por: Lacin, Sahin, et al.
Publicado: (2015)

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012)

Unknown primary large-cell neuroendocrine tumor
por: Póvoa, Sara, et al.
Publicado: (2018)

Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
por: Owen, Dwight H., et al.
Publicado: (2023)

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023)

Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
por: Mirallas, Oriol, et al.
Publicado: (2021)

Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?
por: Chauhan, Aman, et al.
Publicado: (2021)

Spontaneous Tumor Lysis Syndrome Secondary to Small-Cell Neuroendocrine Carcinoma of Unknown Origin: A Rare Case Report and Literature Review
por: Myint, Phyo Thazin, et al.
Publicado: (2019)

Neuroendocrine Tumor of Unknown Primary Accompanied with Stomach Adenocarcinoma
por: Kim, Ho-Yeun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_drou4nip5resieqe1gdoi23gtm